Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes
Research output: Contribution to journal › Journal article › Research › peer-review
To evaluate the dose-response relationship of the recombinant glucagon-like peptide-1 (7-36) amide (rGLP-1) administered by continuous subcutaneous infusion (CSCI) in subjects with type 2 diabetes, with respect to reductions in fasting, postprandial and 11-h serum glucose profiles.
| Original language | English |
|---|---|
| Journal | Diabetes, Obesity and Metabolism |
| Volume | 13 |
| Issue number | 7 |
| Pages (from-to) | 639-43 |
| Number of pages | 5 |
| ISSN | 1462-8902 |
| DOIs | |
| Publication status | Published - 2011 |
- Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glucagon-Like Peptide 1, Humans, Hypoglycemic Agents, Infusions, Subcutaneous, Male, Middle Aged, Peptide Fragments, Placebos, Postprandial Period
Research areas
ID: 40246465